Outcome of small node-negative ER+/HER2+and ER-/HER2+breast cancers might be different

被引：0
|
作者：
Altundag, Kadri [1 ]
机构：
[1] MKA Breast Canc Clin, Ankara, Turkey
来源：
JOURNAL OF BUON | 2020年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：583 / 583
页数：1
相关论文
共 50 条
  • [1] ER+/HER2+AND ER-/HER2+BREAST CANCERS ARE MOLECULARLY DISTINCT BUT IMMUNE GENE SIGNATURES ARE PROGNOSTIC AND PREDICTIVE IN BOTH GROUPS
    Iwamoto, T.
    Pusztai, L.
    Matsuoka, J.
    Callari, M.
    Kelly, C. M.
    Qi, Y.
    Motoki, T.
    Taira, N.
    Santarpia, L.
    Doihara, H.
    Gianni, L.
    Bianchini, G.
    ANNALS OF ONCOLOGY, 2012, 23 : 74 - 75
  • [2] Treatment of ER+/HER2+breast cancer
    Johnston, Stephen
    CANCER RESEARCH, 2023, 83 (05)
  • [3] Role of her3 signaling pathways in er+ and her2+breast cancers
    Mishra, Rosalin
    Alanazi, Samar
    Patel, Hima
    Yuan, Long
    Garrett, Joan T.
    CANCER RESEARCH, 2019, 79 (13)
  • [4] Amplifications, gene fusions, and therapeutic targets in triple negative and refractory ER+ and HER2+breast cancers
    Lai, Zhongwu
    Wu, Haiguo
    Morosini, Deborah
    Webster, Kevin
    Yu, Lihua
    Lenkiewicz, Elizabeth
    Evers, L.
    Holley, T.
    Tembe, Wibhav
    Barrett, Mike
    CANCER RESEARCH, 2012, 72
  • [5] Integrated proteomic and informatic assessment of ER+/HER2-and ER-/HER2-breast tumors
    Wang, Guisong
    Shah, Punit
    Tolstikov, Vladimir
    Raj-Kumar, Praveen-Kumar
    Liu, Jianfang
    Sturtz, Lori A.
    Fantacone-Campbell, J. Leigh
    Zingmark, Rebecca
    Hooke, Jeffrey A.
    Cutler, Mary L.
    Richardson, Kris
    Rodrigues, Leonardo
    Bussberg, Valerie
    Sarangarajan, Rangaprasad
    Narain, Niven R.
    Hu, Hai
    Kiebish, Michael A.
    Kovatich, Albert J.
    Shriver, Craig D.
    CANCER RESEARCH, 2020, 80 (16)
  • [6] Multidimensional metabolomic stratification of ER+/HER2-compared to ER-/HER2-breast tumors.
    Bussberg, Valerie
    Tolstikov, Vladimir
    Wang, Guisong
    Shah, Punit
    Searfoss, Rick
    Fantacone-Campbell, Leigh
    Hooke, Jeffrey A.
    Deyarmin, Brenda
    Zingmark, Rebecca N.
    Somiari, Stella
    Liu, Jianfang
    Kvecher, Leonid
    Mostoller, Bradley
    Sturtz, Lori
    Raj-Kumar, Praveen-Kumar
    Granger, Elder
    Vahdat, Linda
    Cutler, Mary L.
    Bountra, Chas
    Sarangarajan, Rangaprasad
    Hu, Hai
    Kovatich, Albert J.
    Kiebish, Michael A.
    Narain, Niven R.
    Shriver, Craig D.
    CANCER RESEARCH, 2021, 81 (13)
  • [7] ER+/HER2+ Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER-/HER2+ Breast Cancer
    Arciero, Cletus A.
    Guo, Yi
    Jiang, Renjian
    Behera, Madhusmita
    O'Regan, Ruth
    Peng, Limin
    Li, Xiaoxian
    CLINICAL BREAST CANCER, 2019, 19 (04) : 236 - 245
  • [8] A Perimenopausal Woman With a Small, ER/HER2-Positive, Node-Negative Breast Cancer
    Brooks, Gabriel
    Borges, Virginia
    Singh, Meenakshi
    Rabinovitch, Rachel
    Finlayson, Christina
    Elias, Anthony
    ONCOLOGY-NEW YORK, 2008, 22 (11): : 1270 - 1276
  • [9] Therapeutic targeting of Rac GTPases in ER+ and HER2+breast cancer
    Hampsch, R. A.
    Shee, K.
    Miller, T. W.
    CANCER RESEARCH, 2016, 76
  • [10] β2-microglobulin has a different regulatory molecular mechanism between ER+ and ER- breast cancer with HER2-
    Chai, Dandan
    Li, Kesheng
    Du, Huifen
    Yang, Suisheng
    Yang, Rong
    Xu, Yang
    Lian, Xiaowen
    BMC CANCER, 2019, 19 (1)
12345